简介内容：CYH33, an orally active and highly selective PI3Kα inhibitor, demonstrates specificity with IC50 values of nM for the α isoform, 598 nM for β, nM for δ, and 225 nM for γ. It effectively inhibits Akt and ERK phosphorylation and induces substantial G1 phase arrest in breast cancer and non-small cell lung cancer (NSCLC) cells, showcasing potent activity against solid tumors.
Customer Service
